Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease.
Saved in:
| Title: | Outcomes in New User Cohorts of SGLT2 Inhibitors or GLP-1 Receptor Agonists with Type 2 Diabetes and Chronic Kidney Disease. |
|---|---|
| Authors: | Layton JB; RTI Health Solutions, Research Triangle Park, NC, USA., Ziemiecki R; RTI Health Solutions, Research Triangle Park, NC, USA., Johannes CB; RTI Health Solutions, Waltham, MA, USA., Pladevall-Vila M; RTI Health Solutions, Barcelona, Spain.; The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA., Khan AM; RTI Health Solutions, Waltham, MA, USA., Ebert N; Institute of Public Health, Charité-Universitätsmedizin, Berlin, Germany., Kovesdy CP; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA., Christiansen CF; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., García-Sempere A; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Kanegae H; Genki Plaza Medical Centre for Health Care, Tokyo, Japan., Coleman CI; University of Connecticut School of Pharmacy, Storrs, CT, USA.; Evidence-Based Practice Center, Hartford Hospital, Hartford, CT, USA., Walsh M; Division of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada., Andersen IT; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Rodríguez-Bernal C; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Cabaniñas CR; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Thomsen RW; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Farjat AE; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Gay A; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Gee P; National Kidney Foundation Advocacy, Richmond, VA, USA., Hurtado I; Health Services Research and Pharmacoepidemiology Unit, Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO), Valencia, Spain., Kashihara N; Kawasaki Geriatric Medical Center, Okayama, Japan., Munch PV; Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark., Liu F; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Okami S; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Yamashita S; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Yano Y; Department of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan., Vizcaya D; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany., Oberprieler NG; Bayer AG, Müllerstrasse 178, 13353, Berlin, Germany. niki.oberprieler@bayer.com. |
| Source: | Diabetes therapy : research, treatment and education of diabetes and related disorders [Diabetes Ther] 2025 Aug; Vol. 16 (8), pp. 1597-1614. Date of Electronic Publication: 2025 Jun 04. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Country of Publication: United States NLM ID: 101539025 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1869-6953 (Print) Linking ISSN: 18696961 NLM ISO Abbreviation: Diabetes Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1869-6953 |
|---|---|
| DOI: | 10.1007/s13300-025-01750-7 |
